PCIA
AZN icon

Prime Capital Investment Advisors’s AstraZeneca AZN Stock Holding History

Prime Capital Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
9,308
-202
-2% -$38K 0.02% 401
2026
Q1 		$1.88M Sell
9,510
-790
-8% -$152K 0.02% 367
2025
Q4 		$1.89M Sell
10,300
-246
-2% -$43.1K 0.02% 360
2025
Q3 		$1.62M Buy
10,546
+706
+7% +$107K 0.02% 373
2025
Q2 		$1.38M Sell
9,840
-1,710
-15% -$240K 0.02% 408
2025
Q1 		$1.7M Buy
11,550
+1,514
+15% +$219K 0.02% 394
2024
Q4 		$1.32M Sell
10,036
-1,008
-9% -$141K 0.02% 376
2024
Q3 		$1.72M Sell
11,044
-1,034
-9% -$167K 0.02% 336
2024
Q2 		$1.88M Sell
12,078
-714
-6% -$107K 0.03% 321
2024
Q1 		$1.73M Sell
12,792
-310
-2% -$41K 0.02% 367
2023
Q4 		$1.76M Buy
13,102
+5,056
+63% +$657K 0.03% 347
2023
Q3 		$1.09M Buy
8,046
+52
+0.7% +$7.1K 0.02% 330
2023
Q2 		$1.14M Buy
7,994
+3,964
+98% +$583K 0.02% 335
2023
Q1 		$559K Buy
4,030
+1,442
+56% +$194K 0.02% 326
2022
Q4 		$351K Buy
2,588
+752
+41% +$94.3K 0.01% 394
2022
Q3 		$201K Buy
1,836
+43
+2% +$5.46K 0.01% 382
2022
Q2 		$237K Buy
+1,793
New +$235K 0.01% 328
2021
Q2 		– Sell
-435
Closed -$43K – 392
2021
Q1 		$43K Sell
435
-70
-14% -$7.04K ﹤0.01% 348
2020
Q4 		$50K Buy
505
+66
+15% +$6.99K ﹤0.01% 320
2020
Q3 		$48K Buy
439
+1
+0.2% +$111 ﹤0.01% 319
2020
Q2 		$46K Buy
438
+9
+2% +$930 ﹤0.01% 329
2020
Q1 		$38K Sell
429
-3
-0.7% -$282 ﹤0.01% 300
2019
Q4 		$43K Buy
432
+51
+13% +$4.8K ﹤0.01% 318
2019
Q3 		$34K Buy
+381
New +$33K 0.01% 344
2018
Q3 		– Sell
-1,712
Closed -$120K – 261
2018
Q2 		$120K Buy
1,712
+622
+57% +$44.7K 0.05% 147
2018
Q1 		$76K Hold
1,090
– – 0.05% 147
2017
Q4 		$76K Buy
+1,090
New +$73.5K 0.06% 143

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Prime Capital Investment Advisors's AZN Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its AstraZeneca (AZN) stake by 2.1% in Q2 2026, selling an estimated $38K and leaving 9,308 shares worth $1.76M. The position accounts for 0.02% of the portfolio, ranked #401.

Prime Capital Investment Advisors first reported a position in AZN in Q4 2017 and has held it in 27 quarters since. The position peaked at $1.89M in Q4 2025. 1,149 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Prime Capital Investment Advisors held 9,308 shares of AstraZeneca worth $1.76M as of Q2 2026.
  • Prime Capital Investment Advisors sold 202 AstraZeneca shares in Q2 2026, an estimated $38K.
  • AstraZeneca made up 0.02% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #401 holding.
  • Prime Capital Investment Advisors first reported a position in AstraZeneca in Q4 2017 and has held it in 27 quarters since.
  • Prime Capital Investment Advisors's AstraZeneca position peaked at $1.89M in Q4 2025.
  • 1,149 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.